The U.S. Food and Drug Administration (FDA) has expanded the indication for Mounjaro (tirzepatide) to include reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at high risk for cardiovascular events.

The new indication covers cardiovascular death, non-fatal heart attack, and non-fatal stroke. Mounjaro, a dual GIP and GLP-1 receptor agonist, was already approved to improve glycemic control in adults and children age 10 and older with type 2 diabetes. It is now the first dual GIP/GLP-1 receptor agonist with an FDA-approved cardiovascular risk-reduction indication.

The approval is based on results from SURPASS-CVOT, a randomized, double-blind cardiovascular outcomes trial involving 13,299 participants across 640 sites in 30 countries. Unlike many cardiovascular outcomes trials that compare a treatment with placebo, SURPASS-CVOT compared tirzepatide directly with dulaglutide (Trulicity), a GLP-1 receptor agonist with established cardiovascular benefit.

Tirzepatide met the trial's primary objective of demonstrating noninferiority to dulaglutide for the composite outcome of cardiovascular death, heart attack, or stroke. Participants receiving tirzepatide had an 8% lower rate of these events than those receiving dulaglutide, with a hazard ratio of 0.92. The difference did not establish statistical superiority over dulaglutide.

That distinction is important. The headline isn't that Mounjaro proved superior to another cardiovascular-protective incretin. Rather, it demonstrated cardiovascular protection while being tested against an active treatment that already had established cardiovascular benefit, rather than against placebo. SURPASS-CVOT was the first cardiovascular outcomes trial to compare two incretin therapies head-to-head.

The approval also reinforces a broader shift in type 2 diabetes treatment away from focusing primarily on glucose levels. Cardiovascular risk, kidney health, weight, and other outcomes increasingly form part of the overall treatment picture. As cardiometabolic specialist Jennifer Goldman summarized it, treatment decisions increasingly need to account for “glycemia, weight, cardiovascular risk, kidney health, and the whole patient.”

Sources

Eli Lilly: FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Fierce Pharma: Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
HCPLive: Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes
LinkedIn: Jennifer D. Goldman on Mounjaro’s New Cardiovascular Indication